Epizyme Revenue Growth Rates (EPZM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Epizyme Inc.  (NASDAQ: EPZM)
 

EPZM's Revenue Growth by Quarter and Year

Epizyme's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EPZM Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June 27.53
1st Quarter March 8.70
FY 36.23

EPZMs Annual Revenue
Epizyme's Revenue in the fiscal year 2021 $ 37.43 millions
Epizyme's Revenue in the fiscal year 2020 $ 15.76 millions
Epizyme's Revenue in the fiscal year 2019 $ 23.80 millions
Epizyme's Revenue in the fiscal year 2018 $ 21.70 millions
Epizyme's Revenue in the fiscal year 2017 $ 10.00 millions




EPZM Revenue second quarter 2022 Y/Y Growth Comment
Epizyme Inc. reported Revenue surge of 111.59% year on year in the second quarter 2022, to $ 27.53 millions, this is lower than Epizyme Inc.'s recent average Revenue surge of 128.64%.

Looking into second quarter 2022 results within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue growth. While Epizyme Inc.' s Revenue doubling of 111.59% ranks overall at the positon no. 476 in the second quarter 2022.


EPZM Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 38.31 % 95.34 % -55.77 %
3rd Quarter September - 45.66 % -37.59 % -
2nd Quarter June 111.59 % 426.72 % -58.14 % -50.83 %
1st Quarter March 14.02 % 465.19 % -82.89 % -
FY   - 137.35 % -33.74 % -

Financial Statements
Epizyme's second quarter 2022 Revenue $ 27.53 millions EPZM's Income Statement
Epizyme's second quarter 2021 Revenue $ 13.01 millions Quarterly EPZM's Income Statement


EPZM Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 122.88 % 134.73 % -25 %
3rd Quarter September - -60.03 % 44.53 % -3.05 %
2nd Quarter June 216.41 % 70.51 % 82.96 % -25.22 %
1st Quarter March -24.94 % -8.95 % -68.53 % -18.66 %
FY (Year on Year)   - 137.35 % -33.74 % -


Back to EPZM Growth rate Comparisons >> Back to EPZM Growth rate Comparisons >>


Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #109
Overall #476

Revenue Y/Y Growth Statistics
High Average Low
2014.16 % 128.64 % -100 %
(Jun 30 2017)   (Dec 31 2017)
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #109
Overall #476
Revenue Y/Y Growth Statistics
High Average Low
2014.16 % 128.64 % -100 %
(Jun 30 2017)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Epizyme's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1291.97 % 48.48 % -100 %
(Sep 30 2016)  


EPZM's II. Quarter Q/Q Revenue Comment
Epizyme Inc. achieved in the II. Quarter 2022 above company average sequential Revenue doubling of 216.41%, to $ 27.53 millions, from $8.70 millions in the first quarter.
EPZM is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Epizyme's Revenue growth quarter on quarter, overall rank is 161.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #41
Overall #161
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #41
Overall #161
Revenue Q/Q Growth Statistics
High Average Low
1291.97 % 48.48 % -100 %
(Sep 30 2016)  


EPZM's II. Quarter Q/Q Revenue Comment
Epizyme Inc. achieved in the II. Quarter 2022 above company average sequential Revenue doubling of 216.41%, to $ 27.53 millions, from $8.70 millions in the first quarter.
EPZM is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Epizyme's Revenue growth quarter on quarter, overall rank is 161.


Epizyme's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 53.01 $ 38.49 $ 37.43 $ 34.22 $ 32.58
Y / Y Revenue Growth (TTM) 62.7 % 74.65 % 137.45 % 192.93 % 135.59 %
Year on Year Revenue Growth Overall Ranking # 282 # 335 # 123 # 175 # 3634
Seqeuential Revenue Change (TTM) 37.72 % 2.85 % 9.38 % 5.02 % 47.84 %
Seq. Revenue Growth (TTM) Overall Ranking # 829 # 1374 # 1060 # 1577 # 161


Cumulative Revenue growth Comment
Assuming the Epizyme's fiscal year would have ended in Jun 30 2022, Epizyme would have reprted above average annual Revenue growth of 62.7% year on year, of $ 53 millions.
This marks a slow-down of the companys growth trends and from the 74.65% increase in Mar 31 2022.

In the Healthcare sector 68 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 282, from total ranking in previous quarter at 335.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 69
Overall # 282

Revenue TTM Y/Y Growth Statistics
High Average Low
212.77 %
 21.14 %
-93.82 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 70
Sector # 144
S&P 500 # 829
Cumulative Revenue growth Comment
Assuming the Epizyme's fiscal year would have ended in Jun 30 2022, Epizyme would have reprted above average annual Revenue growth of 62.7% year on year, of $ 53 millions.
This marks a slow-down of the companys growth trends and from the 74.65% increase in Mar 31 2022.

In the Healthcare sector 68 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 282, from total ranking in previous quarter at 335.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 69
Overall # 282

Revenue TTM Y/Y Growth Statistics
High Average Low
212.77 %
21.14 %
-93.82 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 70
Sector # 144
S&P 500 # 829




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EPZM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2022
Effector Therapeutics Inc 190.61%$ 190.607 millions
Sunshine Biopharma Inc 184.27%$ 184.274 millions
Xeris Biopharma Holdings Inc 184.15%$ 184.146 millions
Caribou Biosciences Inc 184.01%$ 184.011 millions
Myovant Sciences Ltd 183.69%$ 183.691 millions
Arcus Biosciences Inc 182.83%$ 182.835 millions
Pliant Therapeutics Inc 178.87%$ 178.871 millions
Intra cellular Therapies Inc 177.25%$ 177.250 millions
Akumin Inc 176.46%$ 176.459 millions
Igc Pharma Inc 175.32%$ 175.325 millions
Strata Critical Medical Inc 175.14%$ 175.137 millions
Pear Therapeutics Inc 174.52%$ 174.521 millions
Seer Inc 171.44%$ 171.439 millions
Cormedix Inc 159.47%$ 159.468 millions
Transmedics Group Inc 151.14%$ 151.144 millions
Lftd Partners Inc 150.58%$ 150.577 millions
Guided Therapeutics Inc 150.00%$ 150.000 millions
Intelgenx Technologies Corp 145.68%$ 145.679 millions
Bicycle Therapeutics Plc145.27%$ 145.266 millions
Vbi Vaccines Inc143.66%$ 143.662 millions
Astrotech Corp140.00%$ 140.000 millions
Eton Pharmaceuticals Inc 139.91%$ 139.909 millions
Akebia Therapeutics Inc 139.56%$ 139.561 millions
Aligos Therapeutics Inc 139.03%$ 139.029 millions
Sintx Technologies Inc 137.62%$ 137.624 millions
Rxsight Inc 131.98%$ 131.979 millions
Biohaven Ltd 131.43%$ 131.434 millions
Denali Therapeutics Inc 128.78%$ 128.781 millions
Beone Medicines Ltd 127.73%$ 127.727 millions
Cyclo Therapeutics Inc 127.12%$ 127.120 millions


About Epizyme Revenue Growth Rates (EPZM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Epizyme Inc (CIK 1571498).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-015748
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Epizyme Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.